Now Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind
Elanco Animal Health (NYSE: ELAN) has launched Credelio Quattro, a new monthly chewable tablet for dogs that provides six-in-one parasite protection. The product is the first of its kind to protect against tapeworms, roundworms, hookworms, heartworms, ticks, and fleas in a single tablet.
The launch marks a significant milestone as it completes Elanco's portfolio of six potential blockbuster products in the U.S. market. According to company research, 94% of dog owners prioritize proactive treatment for intestinal worms. Studies show Credelio Quattro is 100% efficacious against tapeworms and kills ticks twice as fast as competing products.
The product addresses a significant market gap, as only one-third of pet owners believe fleas and ticks are a year-round risk, and only half provide year-round heartworm protection.
Elanco Animal Health (NYSE: ELAN) ha lanciato Credelio Quattro, un nuovo tablet masticabile mensile per cani che offre protezione da parassiti sei in uno. Il prodotto è il primo del suo genere a proteggere contro i tenie, i vermi intestinali, i vermi a uncino, i filarie, le zecche e le pulci in un'unica compressa.
Il lancio rappresenta una pietra miliare significativa in quanto completa il portafoglio di Elanco di sei potenziali prodotti di grande successo nel mercato statunitense. Secondo le ricerche aziendali, il 94% dei proprietari di cani dà priorità ai trattamenti proattivi per i vermi intestinali. Gli studi dimostrano che Credelio Quattro è efficace al 100% contro le tenie e uccide le zecche due volte più velocemente rispetto ai prodotti concorrenti.
Il prodotto colma un'importante lacuna nel mercato, poiché solo un terzo dei proprietari di animali domestici crede che pulci e zecche rappresentino un rischio durante tutto l'anno, e solo la metà fornisce protezione contro le filarie tutto l'anno.
Elanco Animal Health (NYSE: ELAN) ha lanzado Credelio Quattro, una nueva tableta masticable mensual para perros que ofrece protección contra parásitos en seis aspectos. Es el primer producto de su clase que protege contra las tenias, los gusanos redondos, los gusanos anquilostomas, los gusanos del corazón, las garrapatas y las pulgas en una sola tableta.
El lanzamiento marca un hito significativo, ya que completa el portafolio de Elanco de seis productos potencialmente exitosos en el mercado estadounidense. Según la investigación de la empresa, el 94% de los propietarios de perros priorizan el tratamiento proactivo para los gusanos intestinales. Los estudios muestran que Credelio Quattro es 100% eficaz contra las tenias y elimina las garrapatas dos veces más rápido que los productos de la competencia.
Este producto aborda una brecha significativa en el mercado, ya que solo un tercio de los propietarios de mascotas creen que las pulgas y las garrapatas son un riesgo durante todo el año, y solo la mitad proporciona protección contra los gusanos del corazón durante todo el año.
엘란코 동물 건강(Elanco Animal Health) (NYSE: ELAN)이 크레델리오 콰트로(Credelio Quattro)를 출시했습니다. 이 제품은 반려견을 위한 새로운 월별 저작형 정제로, 6가지 기생충으로부터의 보호를 제공합니다. 이 제품은 단일 정제로 촌충, 회충, 구충, 심장사상충, 진드기, 벼룩으로부터 보호하는 최초의 제품입니다.
이번 출시로 엘란코는 미국 시장에서 6개의 잠재적 블록버스터 제품 포트폴리오를 완성하게 되었습니다. 기업 연구에 따르면, 94%의 개 주인이 장내 기생충에 대한 적극적인 치료를 우선시합니다. 연구 결과에 따르면, 크레델리오 콰트로는 촌충에 대해 100%의 효능을 보이며, 경쟁 제품보다 진드기를 두 배 더 빨리 죽입니다.
이 제품은 반려동물 소유자의 약 3분의 1만이 벼룩과 진드기가 연중 내내 위험하다고 생각하며, 절반만이 심장사상충 보호를 연중 내내 제공하고 있다는 점에서 중요한 시장의 공백을 해결합니다.
Elanco Animal Health (NYSE: ELAN) a lancé Credelio Quattro, un nouveau comprimé à croquer mensuel pour chiens qui offre une protection contre six types de parasites. Ce produit est le premier de son genre à protéger contre les ténias, les vers ronds, les ankylostomes, les vers du cœur, les tiques et les puces dans un seul comprimé.
Ce lancement marque une étape importante car il complète le portefeuille d'Elanco de six produits à fort potentiel sur le marché américain. Selon des recherches menées par l'entreprise, 94 % des propriétaires de chiens privilégient un traitement proactif contre les vers intestinaux. Des études montrent que Credelio Quattro est efficace à 100 % contre les ténias et tue les tiques deux fois plus vite que les produits concurrents.
Ce produit répond à un besoin important sur le marché, car seulement un tiers des propriétaires d'animaux de compagnie pensent que les puces et les tiques représentent un risque toute l'année, et seule la moitié fournit une protection contre les vers du cœur tout au long de l'année.
Elanco Animal Health (NYSE: ELAN) hat Credelio Quattro auf den Markt gebracht, eine neue monatliche Kautablette für Hunde, die einen Sechs-in-Eins-Parasiten-schutz bietet. Dieses Produkt ist das erste seiner Art, das in einer einzigen Tablette vor Bandwürmern, Rundwürmern, Hakenwürmern, Herzwürmern, Zecken und Flöhen schützt.
Die Markteinführung stellt einen bedeutenden Meilenstein dar, da sie das Portfolio von Elanco mit sechs potenziellen Blockbuster-Produkten auf dem US-Markt vervollständigt. Laut Unternehmensforschung priorisieren 94 % der Hundebesitzer eine proaktive Behandlung von Darmwürmern. Studien zeigen, dass Credelio Quattro zu 100 % wirksam gegen Bandwürmer ist und Zecken doppelt so schnell abtötet wie konkurrierende Produkte.
Das Produkt schließt eine bedeutende Marktlücke, da nur ein Drittel der Tierbesitzer glauben, dass Flöhe und Zecken ganzjährig ein Risiko darstellen, und nur die Hälfte ganzjährig einen Schutz gegen Herzwürmer bietet.
- First-to-market six-in-one parasite protection product
- 100% efficacy against tapeworms
- Superior speed in killing ticks compared to competitors
- Completes portfolio of six potential blockbuster products
- Strong market potential with 94% of dog owners prioritizing worm treatment
- None.
Insights
The launch of Credelio Quattro marks a pivotal moment in Elanco's commercial strategy, potentially reshaping the $5+ billion global parasiticide market. This innovative product addresses several critical market dynamics:
- Market Differentiation: The six-in-one formulation creates a significant competitive advantage, particularly against three-way combinations like Simparica Trio, potentially commanding premium pricing.
- Revenue Potential: With demonstrated superior efficacy and broader protection spectrum, Credelio Quattro could capture substantial market share from existing products while expanding the overall market through improved compliance.
- Strategic Positioning: This launch completes Elanco's strategic portfolio transformation, positioning them as an innovation leader in animal health and strengthening their competitive stance against Zoetis and Merck Animal Health.
- Growth Catalyst: The timing aligns with increasing awareness of zoonotic diseases and year-round parasite protection needs, supported by compelling market research showing low current adoption of comprehensive protection (only 33% of pet owners currently provide year-round protection).
The product's commercial success will likely be driven by its unique value proposition in simplifying parasite protection while potentially reducing overall treatment costs for pet owners. The launch through veterinary channels first, coupled with the VMX conference debut, suggests a strategic focus on building professional advocacy before broader market penetration.
- Six-in-One Parasite Protection in One Chewable Tablet
- Six of Six Potential Blockbusters from Elanco Now In-Market
- Tapeworms
- Roundworms
- Hookwormsii
- Heartworms
- Ticks
- Fleas
"Today is a historic day as we bring veterinarians and pet owners peace of mind with the broadest i parasite protection of its kind for dogs," said Bobby Modi, Executive Vice President,
But the survey shows an important gap where pet owners need to lean in to better protect their beloved pets against risky parasites. Just one in three respondents believe that fleas and ticks are a risk year-round; and only half of dog owners surveyed protect against heartworm disease year-round.iii With the geographic spread of parasites and increasing disease pressure, the importance of year-round protection is more significant than ever.
Broad. Fast. Tasty. Tough.
The broad range of parasite protection from Credelio Quattro in a single, chewable monthly tablet makes it easy for pet parents to protect against some of the most common and challenging parasites. According to studies, Credelio Quattro has been shown to be
"Parasites like tapeworms, fleas and ticks can carry dangerous diseases and some of these can spread from dogs to humans," said Dr. Casey Locklear, veterinarian and parasiticide lead for Elanco Animal Health. "The Companion Animal Parasite Council (CAPC) recommends year round prevention of parasites, even during the winter months and specifically mentions the need for monthly deworming of dogs with praziquantel in areas where a certain type of tapeworm – E. granulosus tapeworms – are endemic."viii
Veterinarians can place their orders today at CredelioQuattroVet.com. Credelio Quattro will make its debut at the Veterinary Meeting & Expo (VMX) in
Launching Credelio Quattro is another milestone in Elanco's historic era of innovation and delivery as it is one of six potential blockbuster products from Elanco available in the
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Indications: Credelio Quattro is indicated for the prevention of heartworm disease and the treatment and control of roundworm, hookworm* and tapeworm infections. Credelio Quattro kills adult fleas and is indicated for the treatment and prevention of flea infestations and the treatment and control of tick infestations for 1 month in dogs and puppies 8 weeks of age and older and weighing 3.3 pounds or greater.
Important Safety Information: Lotilaner, an ingredient in Credelio Quattro, belongs to the isoxazoline class and has been associated with neurologic adverse reactions like tremors, ataxia, and seizures even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Dogs should be tested for existing heartworm infections before Credelio Quattro administration as it is not effective against adult D. immitis. The safe use in breeding, pregnant, or lactating dogs has not been evaluated. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. For complete safety information, please see Credelio Quattro product label or ask your veterinarian.
*Uncinaria stenocephala
NexGard is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. Simparica TRIO is a registered trademark of Zoetis Services LLC.
Credelio Quattro, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2025 Elanco or its affiliates.
____________________ |
i Based on label comparison of the number of parasite types covered in a chewable that covers targets ticks. |
ii Uncinaria stenocephala |
iii Elanco Animal Health, Data on File. February 2024. |
iv Echinococcus granulosus, Dipylidium caninum, and Taenia pisiformis |
v Amblyomma americanum (lone star tick) |
vi Based on the time to statistical significance vs control in a single study on Day 21 and Day 28 for reinfestations. The study compared Credelio™ (lotilaner)—not Credelio Quattro™, which contains lotilaner as well as moxidectin, praziquantel, and pyrantel—to the active ingredients in Simparica Trio™ (sarolaner, moxidectin, and pyrantel) and NexGard™ (afoxolaner). |
vii Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313. |
viii Echinococcus spp. Companion Animal Parasite Council Guidelines. Updated Sept 13, 2022. Accessed Oct 10, 2024. https://capcvet.org/guidelines/echinococcus-spp/. |
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Season Solorio (765) 316-0233 season.solorio@elancoah.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/now-available-credelio-quattro-lotilaner-moxidectin-praziquantel-and-pyrantel-chewable-tablets-provides-broadesti-parasite-protection-of-its-kind-302357947.html
SOURCE Elanco Animal Health
FAQ
What parasites does Elanco's Credelio Quattro (ELAN) protect against?
How effective is Credelio Quattro (ELAN) against tapeworms?
How does Credelio Quattro's (ELAN) tick-killing speed compare to competitors?
When will Credelio Quattro (ELAN) be available for veterinarians to order?
What percentage of dog owners prioritize intestinal worm treatment according to Elanco's (ELAN) research?
